PK/PD bioanalysis helps determine what happens to a biological medicine in the body and how its exposure relates to the biological response. This information is essential during the development of therapeutic proteins, monoclonal antibodies, and other biological products, from preclinical stages through clinical trials.
The development of a biological medicine does not depend solely on demonstrating that a molecule produces the expected effect. It is also necessary to understand how long it remains available in the body, what concentrations it reaches, and how these concentrations relate to its pharmacological activity. Pharmacokinetic (PK) and pharmacodynamic (PD) studies provide complementary information for this purpose.
Having sufficiently sensitive, specific, and reproducible bioanalytical methods is essential for correctly interpreting these data. In addition, regulatory guidelines establish requirements for the validation of methods used to generate data supporting regulatory decisions.
What does pharmacokinetics measure in a biological medicine?
Pharmacokinetics (PK) seeks to answer a basic question: what does the body do to the medicine?
To answer it, the concentration of the medicine is measured in biological matrices such as plasma or serum at different time points after administration.
These measurements can be used to calculate pharmacokinetic parameters such as maximum concentration (Cmax), time to reach maximum concentration (Tmax), area under the concentration-time curve (AUC), half-life, clearance, and volume of distribution.
For example, if concentrations decrease rapidly, it may be necessary to modify the dose or reduce the dosing interval. A longer half-life, on the other hand, may allow for less frequent dosing schedules.
In biological medicines, these studies have specific characteristics compared with small molecules. Their size, structure, and elimination mechanisms can result in complex pharmacokinetic behavior, including nonlinear PK when processes mediated by the therapeutic target are involved.
What does pharmacodynamic analysis add?
While PK examines what the body does to the medicine, pharmacodynamics (PD) asks the opposite question: what does the medicine do to the body?
PD analysis can measure changes in biomarkers associated with the mechanism of action, receptor occupancy, changes in specific proteins, or different cellular processes.
Linking these results to the exposure obtained through PK makes it possible to establish a dose-exposure-response relationship. This can help determine, for example, whether increasing drug concentrations continues to increase the effect or whether the response reaches a plateau.
This information is particularly useful for dose selection and for establishing dosing regimens before moving into larger clinical studies.
From PK/PD bioanalysis to dose selection
Doubling the dose does not necessarily result in twice the exposure or twice the response. PK/PD bioanalysis makes it possible to study this relationship experimentally and determine how concentrations and effects vary according to the administered dose.
During preclinical stages, different dose levels can be analyzed to determine the concentrations reached over hours, days, or weeks. Subsequently, early human trials make it possible to characterize these parameters again and investigate potential differences compared with animal models.
PK/PD data can be used to establish exposure ranges associated with pharmacological activity, identify exposure levels at which the effect no longer increases, and relate specific exposure levels to adverse events.
All this information contributes to defining the doses and dosing intervals that will subsequently be investigated in Phase II and Phase III studies.
The importance of bioanalytical methods
PK/PD data are only useful if the method used to generate them provides reliable and consistent results.
The international ICH M10 guideline establishes harmonized criteria for the validation of bioanalytical methods and the analysis of samples in studies intended to support regulatory decisions.
In the analysis of biological medicines, ligand-binding assays (LBAs) are frequently used to quantify therapeutic proteins. Depending on the characteristics of the analyte and the purpose of the study, certain applications may also use chromatographic techniques and mass spectrometry.
During validation, characteristics such as selectivity, specificity, precision, accuracy, quantification range, and stability are assessed. The potential impact of the biological matrix on the results must also be evaluated.
The objective is to ensure that differences observed in measured concentrations reflect actual changes rather than variations caused by the analytical procedure itself.
Biomarkers and PK/PD analysis during development
The PD component is closely linked to the study of biomarkers. These can provide early evidence that a medicine is acting on the intended biological pathway, even before definitive clinical outcomes are available.
In April 2026, the FDA published specific guidance on the validation of bioanalytical methods used to assess biomarker concentrations, applicable to drug and biological product development programs.
Combining PK, PD, and biomarkers provides a more comprehensive understanding of drug behavior and can support different decisions throughout development. These include dose selection, determination of dosing intervals, formulation comparisons, assessment of exposure-response relationships, and evaluation of variability between patients.
The role of PK/PD bioanalysis in biological medicine development
PK/PD bioanalysis supports the medicine throughout a significant part of its development. It is not limited to determining how much medicine is present in a sample, but also makes it possible to relate measured concentrations to biological activity and help interpret the observed response.
In biological medicines, where structural characteristics and mechanisms of action can result in complex behavior, having appropriate bioanalytical methods is particularly important.
Integrating pharmacokinetic, pharmacodynamic, and biomarker data provides information that can help define doses, dosing intervals, and exposure-response relationships, supporting decisions made throughout the development of the medicine.
Frequently asked questions
- What is PK/PD bioanalysis? PK/PD bioanalysis encompasses the analyses used to generate data on the pharmacokinetics (PK) and pharmacodynamics (PD) of a medicine. It makes it possible to relate drug concentrations in biological matrices to the biological effects produced by the medicine.
- What is PK/PD bioanalysis used for in biological medicines? It is used to study drug exposure, how it changes in the body, and how it relates to the pharmacological response. This information can support dose selection and the determination of dosing intervals during development.
- What is the difference between PK and PD? Pharmacokinetics studies what the body does to the medicine, whereas pharmacodynamics studies what the medicine does to the body. Analyzing both provides insight into the relationship between exposure and response.
- What parameters are obtained in a pharmacokinetic study? Key parameters include maximum concentration (Cmax), time to maximum concentration (Tmax), area under the curve (AUC), half-life, clearance, and volume of distribution.
- Which techniques are used in the bioanalysis of biological medicines? Depending on the medicine and the purpose of the study, techniques such as ligand-binding assays (LBAs), chromatographic methods, and mass spectrometry may be used.
